Prostate Cancer Treatment India – Complete Guide
India's top hospitals treat prostate cancer at 60–80% less than the UK or USA. Learn about success rates, all treatment options, hospital costs, and how to plan
Prostate Cancer Treatment in India: Success Rates, Treatment Options, Costs and Everything International Patients Need to Know Before Deciding (2025)
When a hospital in India says its prostate cancer treatment has a 90 percent success rate, it is telling you something that is both accurate and incomplete.
Accurate, because at India's JCI-accredited cancer hospitals the large majority of men with localised or locally advanced prostate cancer achieve cancer control and outcomes directly comparable to what leading centres in the United Kingdom and United States publish.
Incomplete, because prostate cancer is not one disease.
A man with low-risk disease on active surveillance lives a very different clinical story from a man receiving hormone therapy and radiotherapy for locally advanced cancer — and each has its own definition of success, timeline, and trade-offs.
This guide is written for international patients — from the UK, Nigeria, the UAE, the USA, Bangladesh, Kenya, and Australia — who are seriously evaluating India as the place they want their prostate cancer treated.
| 5-year survival, localised prostate cancer (Stage I–II) | Nearly 100% |
| 5-year survival, locally advanced (Stage III) | ~85–90% |
| Biochemical recurrence-free survival at 10 yr (robotic RP) | 75–85% (low–mid risk) |
| Serious complication rate at JCI hospitals | <3% |
| Robotic prostatectomy cost vs USA | 60–80% lower |
| Positive surgical margin rate (top India centres) | <10% (localised) |
- 1What "success rate" actually means in prostate cancer
- 2Treatment options in India — and which fits your stage
- 3What determines your specific outcome
- 4Cost of prostate cancer treatment in India — full breakdown
- 5India vs UK and USA — are outcomes genuinely comparable?
- 6Best hospitals for prostate cancer in India
- 7Planning your trip — practical guide for international patients
What "Success Rate" Actually Means in Prostate Cancer
When any hospital publishes a prostate cancer success rate, it is measuring one of several different things — and the distinction matters when you are making a real treatment decision.
Overall survival is the most familiar number. For men with localised prostate cancer — disease that has not spread outside the prostate — five-year survival rates at India's JCI-accredited hospitals approach 100 percent.
This is because localised prostate cancer, when treated at a capable centre, is almost always curable. Men diagnosed at this stage do not generally die of it.
Biochemical recurrence-free survival is what oncologists care about most after surgery. After a radical prostatectomy, PSA in the blood should fall to essentially zero and stay there.
If PSA rises to 0.2 ng/mL or above on two consecutive tests, it signals that cancer cells may have remained or returned.
At India's top robotic surgery programmes, biochemical recurrence-free survival at ten years runs 75 to 85 percent for low-to-intermediate-risk disease — consistent with the best published data from the United States and the United Kingdom.
Quality-of-life outcomes — urinary continence, sexual function, bowel health after radiotherapy — are arguably the numbers that matter most in the years after treatment, even when the cancer is controlled.
These vary substantially by treatment type and by the specific skill of the surgeon or radiation oncologist. Aggregate success statistics do not always make these differences visible.
When a hospital publishes a success rate, ask: success measured how, at what time point, and across which stages? A 98 percent rate for stage I disease is a completely different number from a 70 percent rate for stage III — and both may be accurate.
The most useful numbers for an international patient are the positive surgical margin rate, biochemical recurrence-free survival at five years, and the serious complication rate. Ask for those specifically. A hospital confident in its outcomes will share them without hesitation.
| What is being measured | At India's JCI hospitals | What it means practically |
|---|---|---|
| 5-year overall survival (localised) | ~100% | Almost all men with early-stage disease live past 5 years. |
| 5-year survival, locally advanced | 85–90% | Good outcomes with combined hormone therapy + radiotherapy. |
| Biochemical RFS at 10 yr (low risk) | 75–85% | 3 in 4 patients have no PSA recurrence at 10 years. |
| Serious complication rate | <3% | Rare — consistent with UK and US specialist centres. |
| Deep infection rate | <1% | Achieved through laminar flow theatres and strict sterile protocols. |
| Positive surgical margin (localised) | <10% | Consistent with top-volume Western programmes. |
Treatment Options in India — and Which Fits Your Stage
India's top cancer hospitals offer every treatment modality available in the United States or United Kingdom.
The right choice depends primarily on your stage and Gleason score, your age and general health, and your priorities around side effects — particularly urinary continence and sexual function.
Robotic radical prostatectomy (RARP)
Robotic radical prostatectomy using the Da Vinci system is the surgical treatment of choice for localised prostate cancer in men fit enough for a general anaesthetic.
The surgeon operates through five small keyhole incisions using robotic arms controlled from a console, with a magnified three-dimensional view of the operative field that open surgery cannot provide.
Blood loss is typically 100 to 200 millilitres — versus 500 to 1,000 for open prostatectomy. Hospital stay is two to three days rather than five to seven.
The precision of robotic nerve-sparing dissection produces meaningfully better potency preservation rates in experienced hands.
India has over fifteen hospitals with Da Vinci robotic systems. Surgeons at Fortis FMRI, Medanta, and Apollo Delhi perform 150 to 300 robotic prostatectomies per year — directly comparable to specialist volumes at major Western academic centres.
Read the full procedure guide: Robotic prostatectomy in India — Da Vinci Xi system, nerve-sparing technique and what to expect →
See it in practice: Andrew's story — how a 67-year-old from Tanzania had robotic prostatectomy in India and was discharged in 5 days →
External beam radiotherapy — EBRT, IMRT and SBRT
For men who prefer not to have surgery, or who are not surgical candidates, external beam radiotherapy is an equally effective option for localised and locally advanced disease.
India's leading cancer centres operate Varian TrueBeam and Elekta Infinity linear accelerators capable of image-guided IMRT to the same technical specifications as any Western centre.
Stereotactic body radiotherapy (SBRT) delivers the full radiation course in just five sessions. For low-to-intermediate-risk localised prostate cancer, five-year SBRT outcomes are equivalent to conventional radiotherapy.
For an international patient, this means one week of treatment rather than six to eight weeks.
Read the full guide: Radiation therapy for prostate cancer in India — EBRT, SBRT and brachytherapy explained →
Brachytherapy
Brachytherapy places radioactive seeds directly inside the prostate, delivering a very high local radiation dose with minimal exposure to surrounding tissue. It is a day procedure or overnight admission.
Long-term disease control rates for low-to-intermediate-risk disease are equivalent to surgery and external radiotherapy for suitable patients. Available at Fortis FMRI, Apollo Delhi, and several other major Indian centres.
Hormone therapy — androgen deprivation therapy (ADT)
ADT reduces testosterone to near-zero levels, removing the fuel that drives most prostate cancer cells. In locally advanced disease it is almost always combined with radiotherapy — this combination produces significantly better outcomes than either treatment alone.
In metastatic disease it is the primary systemic treatment, increasingly combined with abiraterone or enzalutamide for men with high-volume or high-risk features.
Abiraterone costs over USD 5,000 per month in the United States. The same molecule as a quality-assured generic costs under USD 300 per month in India. For men needing prolonged systemic therapy, this difference alone transforms the financial picture of travelling to India.
Read the full guide: Hormone therapy and ADT for prostate cancer in India — costs, drug access and side effects →
Active surveillance
For men with very low or low-risk prostate cancer — PSA below 10, Gleason 6 (Grade Group 1), disease in fewer than 50 percent of biopsy cores — active surveillance is a clinically endorsed option.
It means monitoring the cancer with regular PSA tests and periodic repeat biopsies, treating only if it shows signs of progression. It avoids all treatment side effects in men whose cancer may never become dangerous during their lifetime.
India's leading uro-oncologists run formal active surveillance programmes and co-manage patients with their local physician at home.
For an international patient this may mean returning to India annually for a monitoring biopsy, or sharing the protocol with a local oncologist who liaises remotely with the Indian specialist.
| Treatment | Best suited for | Stay in India | Cost (India) |
|---|---|---|---|
| Robotic RP (RARP) | Localised, fit patients | 3–4 weeks | USD 3,500–6,000 |
| EBRT / IMRT | Localised or locally advanced | 5–8 weeks | USD 4,000–7,000 |
| SBRT / CyberKnife | Low–intermediate risk | 1–2 weeks | USD 5,000–9,000 |
| Brachytherapy | Low–intermediate risk | 1–2 weeks | USD 4,000–7,500 |
| Hormone therapy (ADT) | Locally advanced, metastatic | Initiated; continued at home | USD 80–150/month |
| Abiraterone (generic) | Advanced / metastatic | Ongoing from home | USD 100–300/month |
| Active surveillance | Very low / low risk | Annual visit for biopsy | USD 300–600/visit |
Not sure which treatment is right for your stage? Get a free specialist case review.
Send your PSA report, biopsy pathology, and imaging to GAF Healthcare. A uro-oncologist reviews your specific case and gives you a written treatment recommendation — not a sales pitch. Free, within 48 hours, no obligation.
Send My Reports for a Free Case Review →What Determines Your Specific Outcome
The aggregate success rate is a population average. Your individual outcome will be higher or lower depending on a set of factors — some in the surgeon's control, some in yours.
Factors the surgeon and hospital control
Surgical volume. This is the single most important factor. Surgeons performing 150 to 300 radical prostatectomies per year produce measurably better surgical margin rates and lower complication rates than those performing 30 to 60.
India's top robotic urology programmes operate at the high end of global volume benchmarks. The uro-oncologists at Fortis FMRI and Medanta perform volumes comparable to the busiest specialist surgeons at major academic centres in the United States.
Multidisciplinary team review. For high-risk or locally advanced prostate cancer, the treatment decision needs a genuine conversation between a urologist, medical oncologist, and radiation oncologist.
Hospitals with formal weekly tumour board meetings produce better treatment plans for complex cases than those where a single specialist makes decisions in isolation.
Infection control. Deep infection after prostate surgery is rare at under 1 percent at JCI-accredited hospitals — but serious when it occurs.
It is prevented through laminar flow operating theatres, HEPA filtration, and prophylactic antibiotics. Ask any hospital you are considering for their published deep infection rate.
Factors you control
Managing your comorbidities before surgery. Patients with poorly controlled blood sugar have significantly higher deep infection rates after prostate surgery — documented across all geographies, not specific to India.
Most surgeons require blood sugar within target range before scheduling elective surgery. Coming to your operation with well-managed chronic conditions is the single most impactful thing a patient with diabetes or hypertension can do to reduce personal complication risk.
Physiotherapy and rehabilitation. Post-operative pelvic floor rehabilitation — starting from the first day after surgery — is essential for urinary continence recovery.
Patients who engage fully with the programme recover continence faster and report significantly better functional outcomes at six months and one year. This is not optional — it is as important as the operation itself.
Not flying home too early. Long-haul flights in the first three weeks after major abdominal surgery carry a significantly elevated DVT risk. Surgeons clear international patients to fly at three to four weeks post-operatively — not earlier.
Three symptoms require same-day attention from your local doctor — not a wait-and-see approach: fever above 38°C (possible infection), calf pain or swelling (possible deep vein thrombosis), and unexpected bleeding from the wound site.
GAF Healthcare provides every patient with a full discharge pack including a red-flag symptom document written for their local doctor, a full procedure summary, and the Indian surgeon's direct contact details. Your surgeon is available for video consultation at six weeks and three months, and by WhatsApp for urgent questions within 24 hours.
Cost of Prostate Cancer Treatment in India — Full Breakdown
The cost of prostate cancer treatment in India is 60 to 80 percent lower than equivalent treatment in the United States, the United Kingdom, or Australia — at hospitals with the same surgical robots, the same radiation systems, and the same accreditation standards.
This is not a quality compromise. It is a structural difference in India's healthcare cost base: labour, infrastructure, and administration are fundamentally cheaper than in Western markets.
For an international patient the relevant comparison is the total episode cost — hospital, surgeon, accommodation, and flights combined. Even adding all of this together, the saving on robotic prostatectomy compared to the United States is typically USD 20,000 to USD 50,000.
The saving on two years of abiraterone therapy can exceed USD 100,000.
| Treatment | India (JCI hospital) | USA (private) | UK (private) |
|---|---|---|---|
| Robotic radical prostatectomy | USD 3,500–6,000 | USD 25,000–55,000 | GBP 12,000–22,000 |
| EBRT / IMRT (full course) | USD 4,000–7,000 | USD 30,000–60,000 | GBP 15,000–28,000 |
| SBRT / CyberKnife (5 sessions) | USD 5,000–9,000 | USD 25,000–50,000 | GBP 12,000–20,000 |
| Brachytherapy (seed implant) | USD 4,000–7,500 | USD 15,000–30,000 | GBP 10,000–18,000 |
| Hormone therapy / LHRH (monthly) | USD 80–150/month | USD 800–1,500/month | GBP 400–900/month |
| Abiraterone (generic, monthly) | USD 100–300/month | USD 5,000–7,000/month | GBP 2,000–3,500/month |
| PSMA PET-CT scan | USD 500–900 | USD 3,000–6,000 | GBP 2,500–4,000 |
| Multiparametric MRI (mpMRI) | USD 200–350 | USD 1,500–3,000 | GBP 700–1,500 |
Accommodation near India's major medical centres costs USD 30 to USD 80 per night for a serviced apartment. Most international surgical patients are in India for three to four weeks.
Even including return flights, the total episode cost for robotic prostatectomy in India — surgery, hospital stay, three weeks' accommodation, and flights — typically stays well under USD 10,000 from the United Kingdom or UAE.
Read the full cost guide: Prostate cancer treatment cost in India — complete breakdown for international patients →
Get a personalised all-in cost estimate for your treatment
Tell us your diagnosis, stage, and preferred treatment type. We give you a written all-in estimate — hospital, surgeon, accommodation, logistics — within 48 hours. Free. No obligation.
Get My Free Cost Estimate →India vs UK and USA — Are Outcomes Genuinely Comparable?
This is the question every international patient finds hardest to answer. The honest answer is yes — at the right hospitals — and the qualifier matters more here than anywhere else in this decision.
JCI accreditation applies the same external quality audit to an Indian hospital as to a hospital in the United States.
The surgical technology is identical — Da Vinci robotic systems are the same machines, same software, same optics at Fortis FMRI and at Johns Hopkins in Baltimore.
The radiation delivery systems are the same Varian TrueBeam and Elekta Infinity linear accelerators used at the Christie in Manchester and Memorial Sloan Kettering in New York. The drugs are the same molecules.
Where India's top hospitals specifically exceed what most Western patients find locally is individual surgeon volume. A patient at a UK district general hospital may be operated on by a surgeon performing 40 to 80 prostatectomies per year.
At Fortis FMRI, Medanta, or Apollo Delhi the same patient has surgery with a surgeon performing 150 to 300. That volume advantage is documented, reproducible, and matters for outcomes in a way that is well established in the surgical literature.
The factor requiring careful attention is selection. The outcomes data that places India's top hospitals on par with Western equivalents applies specifically to JCI-accredited or NABH-platinum-standard facilities with dedicated uro-oncology teams.
It does not apply to every Indian hospital that treats prostate cancer. Choosing by Google ranking rather than accreditation status and documented surgical volume is how patients end up at facilities that do not belong on this comparison.
| Metric | India (JCI / top NABH) | UK / USA equivalent |
|---|---|---|
| 5-year survival, localised disease | ~100% | ~100% |
| Biochemical RFS at 10 yr (low risk) | 75–85% | 75–85% |
| Positive surgical margin (localised) | <10% (top centres) | 8–15% (varies by centre) |
| Annual surgeon volume (RP) | 150–300 (top centres) | 40–80 (typical DGH / NHS) |
| PSMA PET-CT access and cost | Routine · USD 500–900 | Patchy · USD 3,000–6,000 |
| Waiting time for elective surgery | 1–2 weeks | NHS: 6–18+ weeks; Private: 2–6 weeks |
| All-in cost (robotic RP) | USD 3,500–6,000 | USD 25,000–55,000 / GBP 12,000–22,000 |
Best Hospitals for Prostate Cancer in India
The hospitals below are those GAF Healthcare most consistently recommends to international prostate cancer patients, based on documented surgical volumes, accreditation status, radiation technology, multidisciplinary team depth, and direct referral experience built over years.
Fortis Memorial Research Institute, Gurgaon
JCI + NABHThe first recommendation for international patients who need robotic radical prostatectomy. One of North India's highest-volume Da Vinci robotic urology programmes with strong international patient co-ordination and an established pre-travel video consultation process.
Best for: Robotic surgery · complex revision cases · patients who want the highest individual surgeon volume in Gurgaon.
Real patient: Andrew, 67, from Tanzania — robotic prostatectomy, discharged in 5 days →
Read the full Fortis FMRI profile →Medanta – The Medicity, Gurgaon
JCI + NABHThe recommendation for patients with high-risk, locally advanced, or complex disease where the treatment decision is not yet settled. A full oncology campus with surgery, medical oncology, radiation oncology, and nuclear medicine all under one roof — with a formal weekly prostate cancer tumour board and PSMA PET-CT on-site.
Best for: High-risk or locally advanced disease · cases needing multidisciplinary review · patients who want everything under one roof.
Read the full Medanta profile →Artemis Hospital, Gurgaon
NABH PlatinumExcellent surgical outcomes at the most competitive price in Gurgaon. Its uro-oncology surgeons include specialists trained in the UK and USA. For patients with clear localised disease and a settled treatment plan, Artemis offers the best value among Gurgaon's accredited hospitals without any compromise in surgical quality.
Best for: Localised disease · straightforward surgical or SBRT cases · patients prioritising best value in Gurgaon.
Read the full Artemis Hospital profile →Apollo Hospitals, New Delhi
JCI + NABHFlagship campus of India's largest private hospital network. Three decades of international patient co-ordination — more countries, more languages, more first-time medical travellers managed than any other group in India. Full spectrum oncology coverage with Da Vinci robotic surgery, TrueBeam radiotherapy, SBRT, brachytherapy, and PSMA PET-CT all on campus.
Best for: All stages and treatment types · first-time medical travellers to India · patients who want the most established international patient support.
Read the full Apollo Delhi profile →Max Super Speciality Hospital, Saket
JCI + NABHJCI-accredited in South Delhi with particular strength in radiation oncology. For patients whose treatment is EBRT, IMRT, or SBRT — and who prefer South Delhi's direct airport connectivity to the Gurgaon commute — Max Saket's experienced radiation oncology team delivers modern equipment in a well-organised international patient environment.
Best for: Radiation-based treatment · patients staying in central or south Delhi · locally advanced cases needing combined hormone therapy and radiotherapy.
Read the full Max Saket profile →Kokilaben Dhirubhai Ambani Hospital, Mumbai
JCI + NABHMumbai's most technologically advanced JCI-accredited hospital and the recommendation for patients who need CyberKnife SBRT or who prefer Mumbai. Its CyberKnife system delivers real-time tumour tracking and sub-millimetre precision. For patients flying from the Gulf, East Africa, or South-East Asia, Mumbai's direct connections and the one-to-two-week SBRT episode make this the most logistically compact option.
Best for: CyberKnife SBRT · patients flying from the Gulf, East Africa or South-East Asia · localised disease needing a short, self-contained treatment episode in Mumbai.
Read the full Kokilaben profile →Read the full comparison: Best hospitals for prostate cancer in India — accreditation, volumes and outcomes compared →
Not sure which hospital is right for your case?
The right hospital depends on your stage, treatment plan, city preference, and budget. GAF Healthcare reviews your reports and recommends the specific hospital and surgeon — based on documented outcomes, not commercial relationships. Free. Within 48 hours.
Get a Hospital Recommendation for My Case →Planning Your Trip — Practical Guide for International Patients
Travelling to India for prostate cancer treatment involves more co-ordination than most medical procedures.
Prostate cancer treatment often involves a sequence of consultations, imaging, and procedures rather than a single operation. Getting things organised before you travel prevents the stress of working it out on arrival.
Step 1 — Get your records in order before you travel
Any Indian specialist needs your full PSA history, your biopsy pathology report including the Gleason score and which cores were involved, your staging imaging, and a complete blood picture.
Bring physical copies and imaging discs. Most major hospitals accept reports sent electronically in advance for pre-consultation review — this can substantially reduce your time on the ground before treatment starts.
Step 2 — Medical visa
You need an Indian e-MedVisa, not a tourist visa. The application requires a letter from the treating hospital confirming you are seeking care there.
GAF Healthcare provides this letter as standard for every patient. Processing takes three to five working days for most nationalities. Medical visas allow multiple entries and cover the full duration of your treatment episode.
Step 3 — Plan your stay by treatment type
For robotic radical prostatectomy, plan three to four weeks — two to three days hospitalised, then nearby accommodation for wound review and catheter removal, then medical clearance to fly at three to four weeks post-operatively.
For SBRT, one to two weeks covers the treatment and pre-treatment preparation. For conventional EBRT, you will need to stay for the full course — four to eight weeks depending on the protocol.
Step 4 — Confirm your follow-up plan before you leave India
Before flying home, confirm the follow-up protocol in writing with your Indian oncologist. For a post-prostatectomy patient, PSA monitoring every three months for the first two years is standard.
Confirm whether your Indian surgeon will review your PSA remotely, what PSA level should trigger urgent contact, and whether you need a local oncologist at home to co-manage ongoing care.
Having this in writing before departure means you are not navigating it while trying to recover.
"My PSA came back abnormal in June last year. My GP in Manchester said the NHS waiting time for robotic prostatectomy was twelve to sixteen weeks. My wife found GAF Healthcare online. Within a week I had a video call with a surgeon at Fortis who had already reviewed my MRI and biopsy. Six weeks later I was on a plane to Delhi. Three weeks after that I was back home with a PSA of 0.02. The NHS consultant I saw for follow-up was genuinely impressed with the surgical notes and discharge documentation."
Read a full patient story: Andrew Mganga, 67, Tanzania — robotic prostatectomy at Fortis, discharged in 5 days →
Ready to start? Get a free specialist review of your case within 48 hours.
Send your PSA results, biopsy pathology, and imaging to GAF Healthcare on WhatsApp. A uro-oncologist reviews your case — stage, treatment options, hospital and surgeon recommendation, and written cost estimate. Free. No obligation.
Accreditation, surgical volumes, radiation technology, and international patient infrastructure — all six hospitals compared side by side.
Everything about the RARP procedure itself — candidacy, surgical steps, recovery timeline, continence and potency outcomes, and cost breakdown.
A real GAF Healthcare patient from Tanzania with Gleason Grade III prostate cancer who had robotic prostatectomy at Fortis and returned home cancer-free in 5 days.
Which radiation modality fits your stage, how many sessions each requires, and what outcomes to expect at India's leading radiation oncology programmes.
Every procedure cost at each hospital tier, drug pricing for systemic therapy, total trip estimates, and what you save versus the UK or USA.
ADT, abiraterone, enzalutamide — what each costs in India versus the UK and USA, how to manage long-term therapy from home, and what side effects to prepare for.
Have a specific question about your case?
GAF Healthcare's clinical advisors answer specific patient questions — about staging, treatment options, drug availability, surgeon selection, and visa letters — by WhatsApp within 24 hours. We have co-ordinated treatment for patients from over 40 countries.
Ask a Clinical Question on WhatsApp →